Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) and Absci (NASDAQ:ABSI – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.
Profitability
This table compares Arrowhead Pharmaceuticals and Absci’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arrowhead Pharmaceuticals | -160.64% | -172.62% | -37.51% |
| Absci | -8,451.31% | -61.60% | -55.30% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Arrowhead Pharmaceuticals and Absci, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arrowhead Pharmaceuticals | 1 | 3 | 10 | 1 | 2.73 |
| Absci | 1 | 0 | 11 | 0 | 2.83 |
Arrowhead Pharmaceuticals currently has a consensus price target of $98.93, suggesting a potential upside of 116.18%. Absci has a consensus price target of $14.90, suggesting a potential upside of 88.77%. Given Arrowhead Pharmaceuticals’ higher possible upside, equities analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Absci.
Institutional and Insider Ownership
62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.0% of Absci shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Arrowhead Pharmaceuticals has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Absci has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500.
Earnings and Valuation
This table compares Arrowhead Pharmaceuticals and Absci”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arrowhead Pharmaceuticals | $669.50 million | 9.63 | -$724.21 million | ($5.11) | -8.96 |
| Absci | $1.49 million | 910.93 | -$115.18 million | ($0.79) | -9.99 |
Absci has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Absci is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Absci beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.
About Absci
Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
